Articles related to CLINICAL TRIALS

This study highlights repotrectinib’s remarkable efficacy in ROS1 fusion–positive NSCLC, demonstrating a notable response even in patients with the challenging ROS1 G2032R mutation, and presents a new potential standard in targeted lung cancer therapy.

Recent clinical trial findings reveal a significant advancement in Alzheimer’s treatment: combining focused ultrasound with aducanumab shows a notable reduction in amyloid-beta levels in the brain.

At ECTRIMS-ACTRIMS 2023, pivotal studies like the OLIKOS and MIRANTIBUS trials have highlighted the evolving dynamics in MS treatment, particularly emphasizing the shift towards more patient-centric and effective therapeutic approaches.

In a novel approach to combat metastatic castration-resistant prostate cancer, ODM-208, targeting cytochrome P450 11A1, has shown promising results in reducing prostate-specific antigens and testosterone levels, offering new hope in a challenging therapeutic area.

Highlighting a paradigm shift in breast cancer treatment, the NRG Oncology/NSABP B-51/RTOG 1304 study demonstrates that certain patients with node-negative breast cancer post-neoadjuvant chemotherapy may safely omit adjuvant regional nodal irradiation, challenging conventional treatment approaches and potentially improving patient quality of life.

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.